diarrhea in Extend­ed release study [Outliers]

posted by Researcher101 – Egypt, 2020-09-23 23:53 (1583 d 11:38 ago) – Posting: # 21935
Views: 2,744

Dear All, I'm asking if I have a study on product containing two actives (one IR and the other extended release) and a participant had a diarrhea after Tmax of the IR active and through the Tmax of the XR active. should I exclude the participant from the study? or include him in the XR active statistical calculation and exclude in the IR? :confused:

Complete thread:

UA Flag
Activity
 Admin contact
23,368 posts in 4,908 threads, 1,680 registered users;
87 visitors (0 registered, 87 guests [including 7 identified bots]).
Forum time: 10:31 CET (Europe/Vienna)

The mediocre teacher tells.
The good teacher explains.
The superior teacher demonstrates.
The great teacher inspires.    William Arthur Ward

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5